XFOR vs. VCXB, CLLS, CRDF, VXRT, CGEN, CRDL, GNFT, ADVM, VIGL, and ELEV
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include 10X Capital Venture Acquisition Corp. III (VCXB), Cellectis (CLLS), Cardiff Oncology (CRDF), Vaxart (VXRT), Compugen (CGEN), Cardiol Therapeutics (CRDL), Genfit (GNFT), Adverum Biotechnologies (ADVM), Vigil Neuroscience (VIGL), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
10X Capital Venture Acquisition Corp. III (NYSE:VCXB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
X4 Pharmaceuticals' return on equity of 0.00% beat 10X Capital Venture Acquisition Corp. III's return on equity.
10X Capital Venture Acquisition Corp. III has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
X4 Pharmaceuticals has a consensus price target of $3.67, indicating a potential upside of 276.07%. Given 10X Capital Venture Acquisition Corp. III's higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than 10X Capital Venture Acquisition Corp. III.
13.3% of 10X Capital Venture Acquisition Corp. III shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 71.5% of 10X Capital Venture Acquisition Corp. III shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, X4 Pharmaceuticals had 24 more articles in the media than 10X Capital Venture Acquisition Corp. III. MarketBeat recorded 24 mentions for X4 Pharmaceuticals and 0 mentions for 10X Capital Venture Acquisition Corp. III. 10X Capital Venture Acquisition Corp. III's average media sentiment score of 0.10 beat X4 Pharmaceuticals' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.
X4 Pharmaceuticals received 71 more outperform votes than 10X Capital Venture Acquisition Corp. III when rated by MarketBeat users.
Summary
X4 Pharmaceuticals beats 10X Capital Venture Acquisition Corp. III on 7 of the 11 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
